Lexapro and Infectious mononucleosis - a phase IV clinical study of FDA data

Summary:

Infectious mononucleosis is reported as a side effect among people who take Lexapro (escitalopram oxalate), especially for people who are female, 30-39 old, have been taking the drug for 1 - 6 months also take Nuvaring, and have Narcolepsy.

The phase IV clinical study analyzes which people have Infectious mononucleosis when taking Lexapro. It is created by eHealthMe based on reports of 82,231 people who have side effects when taking Lexapro from the FDA, and is updated regularly.

What is Lexapro?

Lexapro has active ingredients of escitalopram oxalate. It is often used in depression. eHealthMe is studying from 91,464 Lexapro users. Check the latest studies of Lexapro.

What is Infectious mononucleosis?

Infectious mononucleosis (infection usually caused by the epstein-barr virus) is found to be associated with 357 drugs and 443 conditions by eHealthMe. Check the latest studies of Infectious mononucleosis.

On Jul, 08, 2026

82,231 people reported to have side effects when taking Lexapro.
Among them, 26 people (0.03%) have Infectious mononucleosis.

Could Lexapro cause Infectious mononucleosis?

Among these 26 people:

How long have people been on Lexapro when they have Infectious mononucleosis? *

What is the gender of people who have Infectious mononucleosis when taking Lexapro? *

female: 87.5 %
male: 12.5 %

What is the age of people who have Infectious mononucleosis when taking Lexapro? *

What are other drugs people take besides Lexapro? *

What are other side effects people have besides Infectious mononucleosis? *

Fatigue (feeling of tiredness): 9 people, 34.62%
Nausea (feeling of having an urge to vomit): 9 people, 34.62%
Headache (pain in head): 9 people, 34.62%
Memory Loss: 8 people, 30.77%
Weight Increased: 7 people, 26.92%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 7 people, 26.92%
Sinusitis (inflammation of sinus): 7 people, 26.92%
Pain: 7 people, 26.92%
Migraine (headache): 7 people, 26.92%
Insomnia (sleeplessness): 7 people, 26.92%

What are the existing conditions these people have? *

Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 11.54%
Acne Cystic (skin problems that cause pimples): 2 people, 7.69%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 7.69%
Birth Control: 2 people, 7.69%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 7.69%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 2 people, 7.69%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 2 people, 7.69%
Osteoporosis (bones weak and more likely to break): 2 people, 7.69%
Fungal Infection: 2 people, 7.69%
Blood Pressure Abnormal: 1 person, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Lexapro and have Infectious mononucleosis?

- Check whether Infectious mononucleosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lexapro:

Lexapro (91,464 reports)

Browse all side effects of Lexapro:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infectious mononucleosis:

Infectious mononucleosis (357 drugs)

Browse all the conditions that are associated with Infectious mononucleosis:

Infectious mononucleosis (443 conditions)

Related publications that referenced our studies

O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .
O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on escitalopram oxalate (the active ingredients of Lexapro) and Lexapro (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.